Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Ciliary Motion01:05

Mechanism of Ciliary Motion

3.7K
The ciliary structures were first seen in 1647 by Antonie Leeuwenhoek while observing the protozoans. In lower organisms, these appendages are responsible for cell movement, while in higher organisms, these appendages help in the movement of the extracellular fluids within the body cavities.
The cilia are made up of microtubules in a 9+2 arrangement, with nine microtubule doublet ring bundles, surrounding a pair of central singlet microtubule bundles. The doublet microtubule bundles are...
3.7K
Gene Therapy00:59

Gene Therapy

25.5K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.5K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

194
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
194
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

791
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
791
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

280
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
280

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association between chronic rhinosinusitis, bronchiectasis and type 2 inflammation: an EMBARC registry analysis.

ERJ open research·2026
Same author

Preclinical human models of primary ciliary dyskinesia.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Comorbid diabetes disease severity and microbial changes in patients with bronchiectasis: a combined analysis of data from the EMBARC, EMBARC-India, Australian, and BE-China registries.

The Lancet. Respiratory medicine·2026
Same author

Nasal nitric oxide combined with clinical features for preliminary screening of primary ciliary dyskinesia in bronchiectasis.

The European respiratory journal·2026
Same author

Frequent exacerbators and neutrophil elastase activity in bronchiectasis: a network analysis approach.

ERJ open research·2026
Same author

Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study.

The Lancet. Respiratory medicine·2026

Related Experiment Video

Updated: Jul 18, 2025

Collection, Expansion, and Differentiation of Primary Human Nasal Epithelial Cell Models for Quantification of Cilia Beat Frequency
11:13

Collection, Expansion, and Differentiation of Primary Human Nasal Epithelial Cell Models for Quantification of Cilia Beat Frequency

Published on: November 10, 2021

4.1K

Restoring Ciliary Function: Gene Therapeutics for Primary Ciliary Dyskinesia.

Nicholas W Keiser1, Erin Cant2, Sneha Sitaraman1

  • 1Spirovant Sciences, Inc., Philadelphia, Pennsylvania, USA.

Human Gene Therapy
|August 25, 2023
PubMed
Summary

Primary ciliary dyskinesia (PCD) is a genetic disorder affecting motile cilia, leading to lung disease. Gene therapy offers a promising future treatment for this complex condition.

Keywords:
AAVciliagene therapylungviral vectors

More Related Videos

High-speed Video Microscopy Analysis for First-line Diagnosis of Primary Ciliary Dyskinesia
05:32

High-speed Video Microscopy Analysis for First-line Diagnosis of Primary Ciliary Dyskinesia

Published on: January 19, 2022

4.4K
Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

4.9K

Related Experiment Videos

Last Updated: Jul 18, 2025

Collection, Expansion, and Differentiation of Primary Human Nasal Epithelial Cell Models for Quantification of Cilia Beat Frequency
11:13

Collection, Expansion, and Differentiation of Primary Human Nasal Epithelial Cell Models for Quantification of Cilia Beat Frequency

Published on: November 10, 2021

4.1K
High-speed Video Microscopy Analysis for First-line Diagnosis of Primary Ciliary Dyskinesia
05:32

High-speed Video Microscopy Analysis for First-line Diagnosis of Primary Ciliary Dyskinesia

Published on: January 19, 2022

4.4K
Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

4.9K

Area of Science:

  • Genetics
  • Pulmonology
  • Cell Biology

Background:

  • Primary ciliary dyskinesia (PCD) is a genetic disorder impacting motile cilia function.
  • Ciliary defects significantly affect multiple organ systems, particularly the lungs, due to impaired airway surface defense.
  • PCD diagnosis presents challenges due to complex testing and overlapping symptoms with other respiratory conditions.

Purpose of the Study:

  • To provide a comprehensive review of primary ciliary dyskinesia (PCD).
  • To cover clinical manifestations, diagnostic approaches, genetic underpinnings, and current management strategies for PCD.
  • To explore PCD model systems and the therapeutic potential of gene therapy for ciliated airway cells.

Main Methods:

  • Literature review of primary ciliary dyskinesia (PCD).
  • Analysis of clinical symptoms, diagnostic methods, and genetic factors associated with PCD.
  • Evaluation of existing and emerging therapeutic strategies, including gene therapy.

Main Results:

  • PCD is a genetically complex disease with diverse clinical presentations, often manifesting as lung disease.
  • Diagnostic challenges persist due to reliance on specialized tests and phenotypic similarities with other respiratory disorders.
  • Several genes are implicated in PCD, and while no cure exists, gene therapy shows therapeutic promise.

Conclusions:

  • Primary ciliary dyskinesia (PCD) is an increasingly recognized genetic disorder affecting cilia, with significant respiratory implications.
  • Effective diagnosis and management of PCD require specialized approaches.
  • Gene therapy represents a key future strategy for treating PCD by targeting defective ciliated cells.